Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?

Executive Summary

NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.

Advertisement

Related Content

Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel